Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Positron Emission Tomography01:29

Positron Emission Tomography

7.9K
Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...
7.9K
Radiological Investigation III: Pulmonary Angiogram and PET Scan01:13

Radiological Investigation III: Pulmonary Angiogram and PET Scan

600
Radiological investigations are paramount in the diagnosis and management of various pulmonary diseases. Two essential investigations are the Pulmonary Angiogram and the Positron Emission Tomography (PET) Scan.
Pulmonary Angiogram
A Pulmonary Angiogram is an invasive procedure involving injecting a contrast medium through a catheter threaded into the pulmonary artery or the right side of the heart to visualize the pulmonary vasculature. Computed Tomography (CT) scans have mainly replaced this...
600
Imaging Studies II: Positron Emission Tomography and Scintigraphy01:25

Imaging Studies II: Positron Emission Tomography and Scintigraphy

705
Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET
705

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Beyond FDG PET in Epilepsy: Radiotracers Targeting Neuroreceptors and Neural Proteins.

AJNR. American journal of neuroradiology·2026
Same author

Longitudinal Tumor Mutation Burden Dynamics in Advanced Prostate Cancer Using Circulating Tumor DNA Profiling.

Clinical genitourinary cancer·2026
Same author

Can Hybrid PET/MRI Advance Precision Imaging in Cardiomyopathy?

Radiology·2026
Same author

Salvage lymph node dissection in oligo-recurrent prostate cancer patients: Mapping patterns of recurrence and factors associated with disease progression.

Urologic oncology·2026
Same author

Biochemical Recurrence Irradiation or Observation (BRIO) in patients with prostate cancer: protocol for a randomised control trial.

BJU international·2026
Same author

MRI Deep Learning for Differentiating Glioblastoma, IDH Wild-type from Central Nervous System Diffuse Large B-cell Lymphoma.

Cancer research communications·2026
Same journal

RETRACTED: Sabir et al. DNA Based and Stimuli-Responsive Smart Nanocarrier for Diagnosis and Treatment of Cancer: Applications and Challenges. <i>Cancers</i> 2021, <i>13</i>, 3396.

Cancers·2026
Same journal

Correction: Adeluola et al. Chemoprevention of 4-NQO-Induced Oral Cancer by the Combination of Resveratrol and EGCG: In Vivo, In Silico and In Vitro Studies. <i>Cancers</i> 2026, <i>18</i>, 1098.

Cancers·2026
Same journal

Correction: Peñalver et al. Guidelines for Diagnosis, Treatment, and Follow-Up of Patients with Follicular Lymphoma-Spanish Lymphoma Group (GELTAMO) 2026. <i>Cancers</i> 2026, <i>18</i>, 395.

Cancers·2026
Same journal

Correction: Accorsi Buttini et al. Development of a Simplified Geriatric Score-4 (SGS-4) to Predict Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation in Patients Aged over 50. <i>Cancers</i> 2025, <i>17</i>, 3278.

Cancers·2026
Same journal

Age-Stratified Long-Term Outcomes of Immune Checkpoint Inhibitors for Stage IV Melanoma and NSCLC in The Netherlands: A Population-Based Study.

Cancers·2026
Same journal

Targeting Ferroptosis in Glioblastoma: Molecular Mechanisms, Tumor Microenvironment, and Therapeutic Opportunities.

Cancers·2026
查看所有相关文章

相关实验视频

Updated: Mar 15, 2026

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods
09:49

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods

Published on: April 24, 2020

10.5K

在PSMA PET/CT上进行PSA零放射性疾病进展.

Ahmed M Mahmoud1, Carter Day2, Eman E Ahmed2

  • 1Department of Radiation Oncology, Kansas University Medical Center, Kansas City, KS 66160, USA.

Cancers
|March 14, 2026
PubMed
概括
此摘要是机器生成的。

前列腺癌可以在放射学上进展,即使PSA水平无法检测. 像PSMA PET/CT这样的先进成像对于早期检测和管理至关重要,无论PSA状态如何.

关键词:
聚乙烯/聚乙烯/聚乙烯前列腺癌是前列腺癌.前列腺特异性抗原 (PSA)前列腺特异性膜抗原 (PSMA)

更多相关视频

A New Technique for Treating Low-risk Prostate Cancer&#8212;Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

1.0K
Implantation and Monitoring by PET/CT of an Orthotopic Model of Human Pleural Mesothelioma in Athymic Mice
07:54

Implantation and Monitoring by PET/CT of an Orthotopic Model of Human Pleural Mesothelioma in Athymic Mice

Published on: December 21, 2019

7.4K

相关实验视频

Last Updated: Mar 15, 2026

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods
09:49

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods

Published on: April 24, 2020

10.5K
A New Technique for Treating Low-risk Prostate Cancer&#8212;Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

1.0K
Implantation and Monitoring by PET/CT of an Orthotopic Model of Human Pleural Mesothelioma in Athymic Mice
07:54

Implantation and Monitoring by PET/CT of an Orthotopic Model of Human Pleural Mesothelioma in Athymic Mice

Published on: December 21, 2019

7.4K

科学领域:

  • 在瘤学瘤学.
  • 核医学是一种核医学.
  • 放射学 放射学是一门学科.

背景情况:

  • 尽管前列腺特异性抗原 (PSA) 水平无法检测,但前列腺癌 (PCa) 的进展可能会发生.
  • 在PCa中,放射性疾病进展 (rDP) 需要进一步调查,特别是在低PSA的背景下.
  • 需要澄清PSMA PET/CT在识别无法检测PSA的rDP中的实用性.

研究的目的:

  • 确定前列腺癌 (PCa) 患者的PSMA PET/CT放射性疾病进展 (rDP) 的频率和特征.
  • 分析PSA零rDP的临床影响,包括进展到抗割PCa和整体存活率.
  • 评估rDP地点与整体存活率 (OS) 之间的关联.

主要方法:

  • 梅奥诊所PSMA PET前列腺癌注册表对rDP和无法检测的PSA患者的分析.
  • 通过活检或治疗反应确认疾病进展.
  • 估计使用卡普兰-梅尔法和日志等级测试进行组比较的整体存活 (OS).

主要成果:

  • 12% (257/2141) 的患者在2021-2023年期间表现出PSA零rDP.
  • 61%的人最初患有局部性疾病,39%的人患有新发转移性疾病.
  • 内脏转移显著与较差的生存状况相关 (p < 0.0001).

结论:

  • 前列腺癌患者经常发展转移性疾病,即使PSA值无法检测.
  • 建议定期进行高级成像,如PSMA PET/CT,不论PSA水平如何,以及时检测进展.
  • 通过先进的成像技术进行早期检测,有助于快速管理PCa进展.